Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. more
Time Frame | ALVR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.82% | -2.82% | 0.15% |
1-Month Return | -15.05% | -4.22% | 1.78% |
3-Month Return | -38.58% | -9.52% | 8.7% |
6-Month Return | -41.77% | -3.45% | 12.24% |
1-Year Return | -78.5% | 5.62% | 30.9% |
3-Year Return | -97.08% | 3.8% | 30.19% |
5-Year Return | -98.19% | 39.68% | 91.72% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 165.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 73.00K | 1.12M | 2.56M | 398.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":2.85,"profit":true},{"date":"2021-12-31","value":43.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.52,"profit":true}] |
Gross Profit | 165.00K | (73.00K) | (1.12M) | (2.56M) | (398.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-44.24,"profit":false},{"date":"2021-12-31","value":-676.97,"profit":false},{"date":"2022-12-31","value":-1554.55,"profit":false},{"date":"2023-12-31","value":-241.21,"profit":false}] |
Gross Margin | 100.00% | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 26.87M | 71.31M | 169.82M | 171.20M | 180.93M | [{"date":"2019-12-31","value":14.85,"profit":true},{"date":"2020-12-31","value":39.41,"profit":true},{"date":"2021-12-31","value":93.86,"profit":true},{"date":"2022-12-31","value":94.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (26.70M) | (71.31M) | (169.82M) | (171.20M) | (181.33M) | [{"date":"2019-12-31","value":-2670100000,"profit":false},{"date":"2020-12-31","value":-7130900000,"profit":false},{"date":"2021-12-31","value":-16981800000,"profit":false},{"date":"2022-12-31","value":-17120200000,"profit":false},{"date":"2023-12-31","value":-18133100000,"profit":false}] |
Total Non-Operating Income/Expense | 4.93M | 2.85M | 178.00K | 4.10M | (3.95M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":57.95,"profit":true},{"date":"2021-12-31","value":3.61,"profit":true},{"date":"2022-12-31","value":83.28,"profit":true},{"date":"2023-12-31","value":-80.23,"profit":false}] |
Pre-Tax Income | (23.84M) | (69.78M) | (170.96M) | (168.97M) | (190.54M) | [{"date":"2019-12-31","value":-2383900000,"profit":false},{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17095500000,"profit":false},{"date":"2022-12-31","value":-16897500000,"profit":false},{"date":"2023-12-31","value":-19054400000,"profit":false}] |
Income Taxes | (2.06M) | (1.40M) | 1.01M | (265.00K) | (126.00K) | [{"date":"2019-12-31","value":-205.06,"profit":false},{"date":"2020-12-31","value":-139.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-26.32,"profit":false},{"date":"2023-12-31","value":-12.51,"profit":false}] |
Income After Taxes | (21.77M) | (68.38M) | (171.96M) | (168.71M) | (190.42M) | [{"date":"2019-12-31","value":-2177400000,"profit":false},{"date":"2020-12-31","value":-6838100000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-19041800000,"profit":false}] |
Income From Continuous Operations | (23.84M) | (69.78M) | (171.96M) | (168.71M) | (168.86M) | [{"date":"2019-12-31","value":-2383900000,"profit":false},{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-16885800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.77M) | (68.38M) | (171.96M) | (168.71M) | (190.42M) | [{"date":"2019-12-31","value":-2177400000,"profit":false},{"date":"2020-12-31","value":-6838100000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-19041800000,"profit":false}] |
EPS (Diluted) | - | (5.17) | (2.74) | (2.25) | (1.67) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-517,"profit":false},{"date":"2021-12-31","value":-274,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-167,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALVR | |
---|---|
Cash Ratio | 86.30 |
Current Ratio | 86.78 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALVR | |
---|---|
ROA (LTM) | -36.53% |
ROE (LTM) | -80.33% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALVR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.01 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.99 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALVR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.48 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.37 |
Allovir Inc (ALVR) share price today is $0.46
Yes, Indians can buy shares of Allovir Inc (ALVR) on Vested. To buy Allovir Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALVR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Allovir Inc (ALVR) via the Vested app. You can start investing in Allovir Inc (ALVR) with a minimum investment of $1.
You can invest in shares of Allovir Inc (ALVR) via Vested in three simple steps:
The 52-week high price of Allovir Inc (ALVR) is $2.45. The 52-week low price of Allovir Inc (ALVR) is $0.45.
The price-to-earnings (P/E) ratio of Allovir Inc (ALVR) is
The price-to-book (P/B) ratio of Allovir Inc (ALVR) is 0.48
The dividend yield of Allovir Inc (ALVR) is 0.00%
The market capitalization of Allovir Inc (ALVR) is $85.25M
The stock symbol (or ticker) of Allovir Inc is ALVR